文献速递免疫规划慢病防控与筛查

HPV疫苗接种对性活跃年轻女性HPV感染发病率及清除率的影响

Impact of HPV vaccination on the incidence and clearance of HPV infections in sexually active young women.
PubMed 文献 · Vaccine · 2025-08-23

在加拿大蒙特利尔开展的卡拉胶凝胶抗宫颈HPV传播试验(2013—2020年)中,461名性活跃女性随访12个月。HPV疫苗接种与HPV 6/11/16/18型新发感染风险降低相关(HR=0.41,95%CI 0.23-0.72),但与同种内及交叉种非疫苗型HPV新发感染无显著关联;对基线HPV感染的清除率也无显著影响。结论认为HPV疫苗具有预防效果,但对现有感染无治疗作用。

要点

  • HPV疫苗接种与HPV 6/11/16/18型新发感染风险降低相关(HR=0.41,95%CI 0.23-0.72)。
  • 疫苗对同种内及交叉种非疫苗型HPV新发感染无显著关联(HR=1.21,95%CI 0.90-1.64;HR=1.21,95%CI 0.94-1.55)。
  • 疫苗对基线HPV 6/11/16/18型、同种内及交叉种HPV感染的清除率均无显著影响。

核心结论

  • HPV疫苗接种是有效的预防措施,但对现有感染无治疗作用。

研究设计与样本

  • 研究基于在加拿大蒙特利尔开展的卡拉胶凝胶抗宫颈HPV传播试验(2013—2020年),共纳入461名性活跃女性,随访12个月,期间进行7次访视。
  • 参与者提供自采阴道样本并完成危险因素问卷,采用Linear Array检测进行HPV基因分型。
  • 采用Cox回归估计HPV感染发病和清除的风险比(HR)及95%置信区间(CI),分析单位为HPV型别。
  • 疫苗接种状态采用严格定义(≥2个来源报告)和非严格定义(≥1个来源报告)进行分析。
  • 使用基于研究和参与者特征的逆概率治疗权重控制混杂。

主要发现

  • 在461名参与者中,按严格定义和非严格定义分别有45.8%和55.5%接种了疫苗。
  • 疫苗接种与HPV 6/11/16/18型新发检出风险降低相关(最严格定义:HR=0.41,95%CI 0.23-0.72;最不严格定义:HR=0.41,95%CI 0.23-0.72)。
  • 疫苗接种与同种内非疫苗型HPV新发感染无显著关联(最严格定义:HR=1.21,95%CI 0.90-1.64;最不严格定义:HR=1.10,95%CI 0.82-1.48)。
  • 疫苗接种与交叉种非疫苗型HPV新发感染无显著关联(最严格定义:HR=1.21,95%CI 0.94-1.55;最不严格定义:HR=1.11,95%CI 0.87-1.41)。
  • 疫苗接种对基线HPV 6/11/16/18型清除无显著影响(最严格定义:HR=1.23,95%CI 0.47-3.24;最不严格定义:HR=1.40,95%CI 0.57-3.47);对同种内非疫苗型HPV清除无显著影响(最严格定义:HR=1.50,95%CI 0.88-2.56;最不严格定义:HR=1.58,95%CI 0.98-2.55);对交叉种HPV清除无显著影响(最严格定义:HR=0.71,95%CI 0.49-1.03;最不严格定义:HR=0.80,95%CI 0.56-1.16)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Human papillomavirus (HPV) vaccination protects against new HPV infections, but seemingly no impact on the clearance of existing infections. We assessed the association between HPV vaccination and incidence and clearance of HPV infections among sexually active women in the Carrageenan-gel Against Transmission of Cervical HPV trial, conducted in Montreal, Canada (2013-2020). METHODS: Participants attended seven visits over 12 months, where they provided self-collected vaginal samples and completed questionnaires on risk factors. Participants self-reported their HPV vaccination status at screening, enrollment, and follow-up visits. Samples were genotyped for HPV using the Linear Array assay. We used Cox regression to estimate hazard ratios (HR) and 95 % confidence intervals (CI) for incidence and clearance of HPV infections, with the unit of analysis being the HPV type. Analyses considered stringent (reported in ≥2 sources) and non-stringent (reported in ≥1 source) definitions of vaccination status. HPV types were classified as vaccine-targeted (HPVs 6/11/16/18) and non-vaccine-targeted (within-species: HPVs 31/33/35/39/44/45/52/58/59/67/68/70; cross-species: HPVs 26/34/40/42/51/53/54/56/61/62/66/69/71/72/73/81/82/83/84/89). To control for confounding, we applied inverse probability of treatment weights, based on study and participant characteristics. RESULTS: Of 461 participants, 45.8 % and 55.5 % were vaccinated according to the stringent and non-stringent definitions, respectively. Vaccination was associated with a lower risk of new HPVs 6/11/16/18 detection in the most stringent (HR = 0.41, CI:0.23-0.72) and least stringent (HR = 0.41, CI:0.23-0.72) definitions. Vaccination was not associated with incident within-species (most stringent: HR = 1.21, CI:0.90-1.64; least stringent: HR = 1.10, CI:0.82-1.48) or cross-species (most stringent: HR = 1.21, CI:0.94-1.55; least stringent: HR = 1.11, CI:0.87-1.41) HPV types. Vaccination did not impact clearance of baseline HPVs 6/11/16/18 (most stringent: HR = 1.23, CI:0.47-3.24; least stringent: HR = 1.40, CI:0.57-3.47), within-species (most stringent: HR = 1.50, CI:0.88-2.56; least stringent: HR = 1.58, CI:0.98-2.55) or cross-species HPV infections (most stringent: HR = 0.71, CI:0.49-1.03; least stringent: HR = 0.80, CI:0.56-1.16). CONCLUSION: We found that HPV vaccination is effective as a prophylactic measure but has no therapeutic effects on existing infections.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Kassam P, Laurie C, El-Zein M, et al. Impact of HPV vaccination on the incidence and clearance of HPV infections in sexually active young women. Vaccine. 2025. PMID: 40850293. doi:10.1016/j.vaccine.2025.127632

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。